Search PubMed⌕ Search

Biomedical subjects

G Samsioe

Publications and source records attributed to G Samsioe.

At least 91 records · Page 5Linked to original sources
PubMed1985

Oral replacement with estradiol-cyclooctyl acetate: a new estradiol analogue. Effects on serum lipids, proteins, gonadotrophins, estrogens and uterine endometrial morphology.

Estradiol-cyclooctyl acetate (E2CoA) dissolved in arachis oil was given orally at a dose of 0.5 mg/day for 21 days to 11 oophorectomized women. The study was performed in two steps. In the first step the effects of E2CoA, administered after an overnight fast, on plasma estrone, estradiol, FSH, LH, prolactin as well as on serum proteins, fatty acids, oral glucose tolerance test and on the cervical and endometrial morphology were compared to the effects of daily oral intake of 25 micrograms ethinyl estradiol (EE) in a cross-over study. In the second step the effects of E2CoA in nonfasting conditions on plasma estrone, estradiol, FSH and LH were studied. E2CoA alleviated climacteric estrogen-deficiency symptoms in all women. It showed an estrogenic effect on cervical and endometrial morphology and depressed FSH, though more weakly than EE. No side effects were seen. The unchanged metabolic parameters after 21 days of E2CoA treatment may support the assumption of a weak estrogenic effect, but the relatively slow resorption and relatively low estradiol/estrone ratio found in this study do not confirm the hypothesis that the drug is resorbed by the chylomicrones. Further investigation on the resorption of E2CoA in nonfasting women is, however, needed.

Adult↗
PubMed1985

Some new aspects on emesis gravidarum. Relations to clinical data, serum electrolytes, total protein and creatinine.

Although nausea and vomiting in early pregnancy is extremely common, very little information on the cause and course of this disorder is available in the literature. A prospective laboratory and clinical study of 102 consecutive healthy pregnant women was undertaken to evaluate nausea and vomiting in relation to clinical data, serum electrolytes, creatinine, total protein and hemoglobin. Multigravidae suffered from emesis gravidarum at a higher rate than did primigravidae. The frequency of emesis was especially high in women with short intergestational intervals. During pregnancy there was a decline in systolic blood pressure only in non-emetic women. The diastolic blood pressure in late pregnancy was significantly higher in emetic women than in non-emetic subjects. All laboratory values were within normal ranges. However, major changes occurred during pregnancy but some alterations were noted only in the emetic pregnancy. A different response to the hormonal situation is suggested to explain the dissimilarities between the emetic and non-emetic pregnancy.

Adult↗
PubMed1985

Effects of a low-dose desogestrel-ethinylestradiol combination on hirsutism, androgens and sex hormone binding globulin in women with a polycystic ovary syndrome.

Twenty women suffering from a polycystic ovary syndrome (PCO) accompanied by hirsutism were given a low-dose oral contraceptive combination containing 0.150 mg desogestrel plus 0.030 mg ethinylestradiol for 8 months. The pretreatment situation regarding hair and hormone profiles in the PCO group was compared with that in 22 regularly menstruating women. Serum levels of free and total testosterone and androstenedione were significantly elevated in PCO women, as were body weight, blood pressure, hair diameter and depilation frequency. Sex hormone binding globulin (SHBG) binding capacity was lower. Following treatment of the PCO group for 8 months, total and free testosterone levels were depressed, but androstenedione had not changed significantly. SHBG binding capacity was increased five-fold. Body weight decreased in the obese women. Hair growth was significantly suppressed and the hair itself was less coarse. Depilation intervals were longer. Acne, present before the treatment had now disappeared. Blood pressure did not change. Few and mild side effects were recorded. After treatment, 3 women succeeded in becoming pregnant and in 8 others spontaneous menstruations had recurred.

Adult↗
PubMed1985

Lipid metabolic studies in women with a polycystic ovary syndrome during treatment with a low-dose desogestrel-ethinylestradiol combination.

Twenty women with the polycystic ovary syndrome (PCO) were treated with a combination of desogestrel and ethinylestradiol (EE) and the effects on lipids and lipoproteins were compared with those induced in a group of 13 regularly menstruating, healthy women. All women were examined before and after 3 months of treatment. Compared with the regularly menstruating women, the PCO women had significantly higher body weights and blood pressure as well as elevated levels of triglycerides in serum and VLDL. During treatment, 14 out of 20 women affected by PCO lost weight. No significant change in blood pressure was observed. In the PCO group, moderate increments were encountered in serum cholesterol, phospholipids and triglycerides. No significant changes were seen in LDL-cholesterol or HDL-cholesterol. The ratio LDL-cholesterol/HDL-cholesterol did not alter. The level of total cholesterol in VLDL rose during treatment. These changes in serum and lipoprotein lipids in PCO patients were of the same type and magnitude as those found in the control group, apart from an increase in HDL-cholesterol in the latter. The only remaining difference after treatment was a slightly higher level of VLDL triglycerides in the PCO women. Thus only moderate changes were induced in lipid and lipoprotein patterns by the combination of desogestrel and EE. A "positive" influence on lipids and lipoproteins cannot be considered as a further advantage, added to the list of indications when hormonal treatment is used in PCO-affected women. The clinical implications of elevated triglycerides remain to be clarified.

Adult↗
PubMed1985

Estrogen-progestogen replacement in climacteric women, particularly as regards a new type of continuous regimen.

Twenty-six peri- and postmenopausal women were treated with daily dose of 2 mg 17-beta-estradiol, 1 mg estriol and 1 mg norethisterone-acetate in a continuous regimen for 12 months. Clinical parameters such as vasomotor symptoms, bleeding patterns and histopathology were recorded. Blood samples were collected before, after 3 months and after 12 months of treatment and were analysed for estradiol-17-beta, estrone, androstenedione in serum and lipoprotein lipids. A marked reduction of hot flushes and sweatings was noted and the number of days with bleeding gradually decreased during treatment, especially in the postmenopausal group of women. No signs of hyperplasia of the endometrium were recorded. A decrease in the serum concentration of testosterone and androstenedione was found during treatment. The reduction in triglycerides in very low density lipoproteins after 3 months, concomitant with a decrease in the cholesterol content of high density lipoproteins, was interpreted as an effect mainly of the progestogen component in the preparation. The present formulation of estrogen-progestogen, continuously administered, may be an appropriate alternative treatment regimen for many women. One proposition of how to treat women with climacteric complaints around the menopause is presented.

Adult↗
PubMed1984

Changes in relative fatty acid composition of serum lecithin and cholesterol ester after treatment with two gonane progestins administered alone and in combination with ethinyl estradiol.

Twenty women, oophorectomized as part of treatment for cervical carcinoma of the cervix participated in the study. Ten of them were given desogestrel (DG) 150 micrograms/day for 3 weeks followed by DG + 30 micrograms ethinyl estradiol (EE) for 6 weeks, and finally EE alone for 3 weeks. The other 10 women were given 150 micrograms levonorgestrel (NORG) and EE in a similar way. Before treatment and after each period of treatment the relative fatty acid composition of serum lecithin and serum cholesterol ester were assessed by gas-liquid chromatography. In both groups ethinyl estradiol, when administered alone, increased arachidonic acid in serum lecithin. This increase was not observed on the DG + EE or the NORG + EE combination indicating that both progestins counteracted this estrogenic effect.

Adult↗
PubMed1984

The fatty acid composition of serum lecithin after pregnancy complicated by pre-eclampsia.

Using gas-liquid chromatography the relative fatty acid composition of serum lecithin was measured in 22 women, during and after pregnancies complicated by pre-eclampsia, and the results were compared with those in 21 "normal" puerperal women. The increased values of 22:6 in the linolenic acid series found during pregnancy in women who had pre-eclampsia were also noted in the puerperium and the 22:6 value fell to normal more slowly. This might be due to an enhanced activity of the deacylation-reacylation cycle in this group of patients. All other fatty acids showed a rapid return to normal with values comparable to those of "normal" puerperal women 1 week after delivery. The differences in essential fatty acid distribution between normal and pre-eclamptic women did not seem to have a dietary cause. The prostaglandin precursors (arachidonic and dihomo-gamma-linolenic acids) were not reduced during pre-eclampsia or in the puerperium. Neither breast-feeding nor treatment of hypertension with hydralazine seemed to influence the fatty composition of serum lecithin.

Adult↗
PubMed1984

Lipid composition of serum lipoproteins in relation to gonadal hormones during the normal menstrual cycle.

Twenty-two normally menstruating women were studied during one menstrual cycle. Blood was collected on 4 occasions and was analysed for free and total cholesterol and triglycerides and phospholipids in the lipoprotein fractions, very-low-density lipoproteins (VLDL), low-density lipoproteins (LDL) and high-density lipoproteins (HDL). Fluctuations in lipid parameters were correlated to serum levels of estradiol-17 beta, progesterone, androstenedione, testosterone and sex-hormone-binding globulin (SHBG). Elevated concentrations of SHBG and HDL-cholesterol and a suppression of LDL-cholesterol were found during the luteal compared to the follicular phase and these findings were interpreted as an estrogenic influence. Consequently the ratio LDL-cholesterol/HDL-cholesterol was depressed during the luteal phase. Triglycerides in serum and VLDL reached a peak at midcycle. When effects on lipid metabolism induced by endogenous steroids were compared to lipoprotein fluctuations exerted by exogenous hormones a parallelism was found in certain variables. However, obvious discrepancies were also found in effects on lipid metabolism, especially for hormones with androgenic properties. The present data underline the necessity of defining in which menstrual phase blood has been collected when lipid metabolism is studied in women of fertile age. Knowledge about metabolic events induced by exogenous sex steroids does not allow conclusions concerning the effects exerted by corresponding endogenous hormones.

Adolescent↗
PubMed1984

Apolipoprotein A1 levels in oophorectomized women treated with Org OD 14, oestradiol valerate and a placebo.

Org OD 14 is a synthetic steroid which in animal bioassays displays oestrogenic as well as very weak androgenic-anabolic properties. Earlier studies have shown that it alleviates oestrogen-deficiency symptoms and retards osteoporosis. OD 14 can be administered continuously with little effect on the endometrium. The aim of this study was to evaluate the effect of OD 14 on apolipoprotein A1 (Apo-A1), the major protein constituent of the high-density lipoprotein (HDL) fraction, as compared with that of oestradiol valerate (E2V) and a placebo. Twenty-two women, who had been oophorectomized when undergoing surgical treatment for stage IB or IIA cervical carcinoma, were given OD 14 2.5 mg/day, a placebo, and E2V 2 mg/day for a period of 6 wk in each case using a double-blind, cross-over method. Serum Apo-A1 was determined by electro-immunoassay after each treatment period. There was a marked decrease in Apo-A1 after OD 14 as compared with the levels seen after the placebo and E2V. This decrease is interpreted as evidence of a strong androgenic influence by OD 14. In epidemiological studies low levels of Apo-A1 have been associated with a higher incidence of atherosclerosis and cardiovascular disease. Long-term treatment with OD 14 might therefore be hazardous in this respect.

Adult↗
PubMed1984

Changes in serum apo-lipoprotein AI and sex-hormone-binding globulin levels after treatment with two different progestins administered alone and in combination with ethinyl estradiol.

Twenty women, oophorectomized as part of the surgical treatment for cervical carcinoma in either clinical stage IB or IIA but otherwise healthy, participated in the study. After a period of six weeks without hormonal treatment, ten of them were given 150 micrograms desogestrel (DG) daily for three weeks followed by 150 micrograms DG + 30 micrograms ethinyl estradiol (EE) for six weeks and, finally, 30 micrograms EE alone for three weeks. The remaining ten women were given 150 micrograms levonorgestrel (NORG) and EE in a similar regimen. Before treatment and after each period of treatment, apo-lipoprotein AI and sex-hormone-binding globulin (SHBG) were assayed in serum. Both progestins decreased apo-AI and SHBG when given alone, thereby indicating an "androgenic" influence. In combination with EE, however, DG seems to be less "anti-oestrogenic" than NORG, as judged from the higher apo-AI and SHBG values after the combination DG + EE compared to those after NORG + EE.

Adult↗
PubMed1984

Lipid metabolism in women with polycystic ovary syndrome: possible implications for an increased risk of coronary heart disease.

This study reports values of serum lipids, lipoproteins, and the relative fatty acid composition of lecithin and cholesterol ester in 20 women with typical polycystic ovary syndrome (PCO). These values were compared with values of 22 regularly menstruating women without clinical evidence of androgen excess. Higher levels of triglycerides in serum (P less than 0.05) and very low-density lipoproteins (P less than 0.01) and lower concentrations of free cholesterol in low-density lipoproteins (P less than 0.05) were found in the PCO women. In serum lecithin the PCO patients had higher palmitic and lower stearic acid levels compared with those of the normal women. This finding was interpreted as a reduction of the excretory capacity of the liver in the PCO group. No correlations between lipids and sex hormones were found. Body weights and blood pressures were higher in the PCO group. The results indicate that PCO women could be at increased risk for coronary heart disease, because an increased serum triglyceride level, body weight, and blood pressure are considered to be risk factors of coronary heart disease.

Adult↗
PubMed1984

Changes in apolipoprotein AI after treatment with high-dose medroxyprogesterone acetate.

21 women (mean age 60 years, range 48-72) were given depot medroxyprogesterone acetate (DMPA), 1,000 mg/week parenterally for 6 months, as part of the treatment for endometrial carcinoma in either clinical stage I or II. Before treatment and after 1, 3 and 6 months of treatment serum apolipoprotein AI was analyzed by electroimmunoassay. There was a significant decrease in apolipoprotein AI after the administration of DMPA, compared to the value before treatment. A low level of apolipoprotein AI is considered a risk factor for the development of atherosclerosis and cardiovascular disease. Such a risk might therefore be anticipated if the period of treatment was extended to several years.

Aged↗
PubMed1984

A continuous estrogen-progestogen regimen for climacteric complaints. Effects on lipid and lipoprotein metabolism.

The lipid composition of serum and the lipoprotein fractions, very low density lipoprotein (VLDL), low density lipoprotein (LDL) and high density lipoprotein (HDL) were determined in 26 peri- and postmenopausal women treated with a daily dose of 2 mg 17-beta-estradiol, 1 mg estriol and 1 mg norethisteroneacetate in a continuous regimen for 12 months. A decrease was noted in all serum lipids, triglycerides, cholesterol and phospholipids during treatment. When comparing the lipid values after 3 and 12 months of treatment a tendency was found to approach pretreatment values with time. A reduction of triglycerides in VLDL after 3 months, concomitant with a decrease in HDL-cholesterol, was interpreted as an effect mainly of the progestogen component. A decrease of free cholesterol in LDL was found during treatment. The ratio of LDL-cholesterol/HDL-cholesterol was unaltered when comparing values before vs. after 3 and 12 months of treatment. Decreased levels of HDL-cholesterol and elevated levels of LDL-cholesterol are considered to be risk factors for coronary heart disease. The significance of lipid metabolic effects induced by treatment in the present study on a longterm basis is hard to evaluate in terms of atherogenicity.

Adult↗
PubMed1984

Effects of two estradiol/norgestrel combinations on the ovulatory pattern and on sex hormone binding globulin capacity in women around forty years of age.

Thirteen women aged 36-46 years (mean 43) who were seeking contraceptive advice, were monitored for 3 months with basal body temperature (BBT) and were then treated for 3 months with CyclabilR (11 tablets of 2 mg estradiol valerate (E2) followed by 10 tablets of 2 mg E2 + 0.5 mg norgestrel). This treatment was immediately followed by another 3 months with CyclabilR + 2 mg E2. BBT revealed a spontaneous ovulatory rate of 89%. Cyclabil reduced the ovulatory rate, as measured with repeated serum progesterone analyses, to 37%, and Cyclabil + 2 mg E2 resulted in a marked reduction in the number of ovulations (3%). Both types of hormonal combination resulted in relatively small changes in Sex Hormone Binding Globulin Capacity. It is concluded that the addition of 2 mg E2 to CyclabilR causes a decrease in ovulation rate to such an extent that women using this combination run a relatively small risk of conceiving. One advantage over contraceptive steroids may be that the present combination contains a natural estrogen at a relatively low concentration.

Adult↗
PubMed1983

Effects of a continuous estrogen-progestogen therapy for climacteric symptoms on circulating sex steroids and gonadotrophins.

Twenty-six peri- and postmenopausal women with climacteric symptoms were given each day for 1 year a tablet containing 2 mg 17-beta-estradiol, 1 mg estriol and 1 mg norethisterone acetate. Blood samples were collected before, after 3 months and after 12 months of treatment and were analysed for their gonadotrophins, estradiol, estrone, testosterone, androstenedione content and for their SHBG binding capacity. Serum levels of estrone and androstenedione before treatment were found to be higher in the perimenopausal than in the postmenopausal group. An increase of serum estrogens concomitant with a decrease of gonadotrophins was noted. The estrone/estradiol ratios after 3 and 12 months of treatment were 5.3 and 4.7, respectively. A decrease in the serum concentration of testosterone and androstenedione was recorded during treatment. The reduction of gonadotrophins, especially LH, might have been responsible for the reduction in circulating androgens. The reduction of serum levels of androgens during the present long-term replacement therapy could be of metabolic importance.

Adult↗